ginning with 2020), such payment amounts for a month shall be made on the first business day occurring on or after the following date for that month:

“(A) For the month of January, January 2nd.

“(B) For the month of February, February 5th.

“(C) For the month of March, March 10th.

“(D) For the month of April, April 15th.

“(E) For the month of May, May 20th.

“(F) For the month of June, June 25th.

“(G) For the month of July and each succeeding month (other than December) in a year, the first day of the next month.

“(H) For the month of December, December 24th.”.

Subtitle B—Cures Innovation Fund

SEC. 4041. CURES INNOVATION FUND.

(a) ESTABLISHMENT.—There is hereby established in the Treasury of the United States a fund to be known as the Cures Innovation Fund (in this section referred to as the “Fund”).

(b) APPROPRIATIONS.—There is hereby appropriated to the Fund, out of any funds in the Treasury not other-
wise appropriated, $110,000,000 for each of fiscal years
2016 through 2020.

(c) EXPENDITURES.—Amounts in the Fund shall be
available, as provided by appropriation Acts, for making
expenditures for carrying out the following:

(1) Section 229A of the Public Health Service
Act, as added by section 1123 (relating to data on
natural history of diseases).

(2) Part E of title II of the Public Health Serv-
ice Act, as added by section 1141 (relating to Coun-
cil for 21st Century Cures).

(3) Section 2001 and the amendments made by
such section (relating to development and use of pa-
tient experience data to enhance structured risk ben-
efit assessment framework).

(4) Section 2021 and the amendments made by
such section (relating to qualification of drug devel-
lopment tools).

(5) Section 2062 and the amendments made by
such section (relating to utilizing evidence from clin-
ical experience).

(6) Section 2161 (relating to grants for study-
ing the process of continuous drug manufacturing).
(c) **Supplement, Not Supplant; Prohibition Against Transfer.**—Funds appropriated by subsection (b)—

(1) shall be used to supplement, not supplant, amounts otherwise made available to the National Institutes of Health and the Food and Drug Administration; and

(2) notwithstanding any transfer authority in any appropriation Act, shall not be used for any purpose other than the expenditures listed in subsection (c).

**Subtitle C—Other Reforms**

**SEC. 4061. SPR Drawdown.**

(a) **Drawdown and Sale.**—Notwithstanding section 161 of the Energy Policy and Conservation Act (42 U.S.C. 6241), the Secretary of Energy shall draw down and sell 8,000,000 barrels of crude oil from the Strategic Petroleum Reserve during each of the fiscal years 2018 through 2025, except as provided in subsection (b).

Amounts received for a sale under this subsection shall be deposited in the General Fund of the Treasury during the fiscal year in which the sale occurs.

(b) **Emergency Protection.**—The Secretary shall not draw down and sell crude oil under this section in amounts that would result in a Strategic Petroleum Re-